Oramed Pharmaceuticals Reports Positive Results For Diabetes Study

Oramed Pharmaceuticals has reported positive results from a phase 2A study of oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The study evaluated safety, tolerability and food effects in type 1 diabetic patients.

Oramed’s oral insulin capsule (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion, said the company.

Miriam Kidron, chief scientific officer of Oramed, said: “These results demonstrate that Oramed’s oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal.”

Currently, Oramed is conducting phase 2B clinical trial in South Africa to evaluate the effects of ORMD-0801 on type 2 diabetic patients.